setrusumab (UX143) — Regulatory decision
Late 2026
Mereo and partner Ultragenyx engaging with regulatory agencies on potential path forward for setrusumab in osteogenesis imperfecta (OI); further updates expected by year-end 2026Source filing
MREO biotech catalysts & pipeline
MEREO BIOPHARMA GROUP PLC · Data as of 2026-09-08